OX401

OX401 is a **preclinical oligonucleotide oncology candidate** from **Onxeo** developed from the company's **platON** platform. It is described as a **PARP1 agonist** with a **decoy agonist** mechanism that hyperactivates PARP signaling rather than inhibiting PARP, leading to disruption of tumor-cell DNA damage response pathways. Preclinical data also indicate activation of the **cGAS-STING** innate immune pathway, with downstream induction of antitumor innate and adaptive immune responses. The program is being developed for **solid tumors**, including **breast cancer models**, and has been studied both as monotherapy and in combination with **checkpoint inhibitor immunotherapies**. Reported preclinical features include selective activity in cancer cells, strong antitumor efficacy, and lack of observed resistance induction in the cited models.